T issue factor (TF) is a 47-kDa transmembrane glycoprotein that activates the coagulation cascade and is considered to be a major regulator of coagulation, hemostasis, and thrombosis. 1 TF expression is regulated in a cell-specific manner. The protein is constitutively expressed by a number of extravascular cell types, [2] [3] [4] whereas normally it is not expressed by cells that are in direct contact with blood, such as the endothelium lining normal arteries and circulating monocytes. However, numerous agents, eg, cytokines and growth factors, induce TF in blood monocytes and cultured endothelial cells. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Functional TF is present at high levels on the surface of stimulated human monocytes. 2, 15, 16 Studies with endothelial cells, on the contrary, indicate that little or no TF is present on the surface of agonist-induced endothelial cells, suggesting that these cells handle newly synthesized TF differently from monocytes or other cells constitutively expressing the protein. 7, [17] [18] [19] Regulation of TF synthesis is predominantly at the level of transcription and mRNA stabilization. 11,20 -22 After its synthesis, TF protein can be translocated to the cell surface, where it binds factor VII. The TF/factor VIIa complex activates factors IX and X, thus triggering coagulation. In this context, the expression of TF may be relevant to pathophysiological conditions only if it results in increased surface expression of TF.
The relationship between total TF synthesis and surface TF expression has not been fully elucidated. Data suggest that exposure of endothelial cells to recombinant tumor necrosis factor-␣ (rTNF-␣), though inducing substantial amounts of total TF, results in limited expression of active protein on the cell surface. 18 Several agonists can potentiate the effect of rTNF-␣, inducing endothelial cells to synthesize very high levels of TF. 7, 13 No information, however, is available concerning the effect of this potentiation on the surface expression of functional TF.
In this study, we examined the localization of TF antigen and activity on human umbilical vein endothelial cells (HUVECs) in response to recombinant vascular endothelial growth factor (rVEGF) and rTNF-␣ by employing immunohistochemical techniques and a parallel-plate perfusion system. Whereas either agonist alone induced little surface TF activity, the combination of the 2 agonists resulted in a Ͼ100-fold increase in surface TF activity. These data were confirmed by immunolocalization of TF: almost no staining was seen in control cells or in cells treated with a single agent, whereas cells treated with both agonists showed intense membrane staining.
Methods

Materials
PBS, medium 199, L-glutamine, penicillin, and streptomycin were from GIBCO Laboratories. FCS was from Mascia Brunelli. rTNF-␣ was obtained from Genentech. rVEGF, a 165-amino acid variant of human VEGF, was from R&D Systems. All cell culture reagents and solutions were checked for endotoxin contamination in the Limulus lysate chromogenic assay (Coatest endotoxin, Kabi Diagnostica). All reagents and media contained Ͻ50 pg/mL lipopolysaccharide.
Human coagulation factor VIIa was purchased from Novo Nordisk A/S 2880. Human coagulation factor X was purified as previously described. 23 The chromogenic substrate for activated factor X, Ile-Pro-Arg-p-nitroaniline (IPR-pNA) was synthesized in our laboratory. PMSF, benzamidine, and aprotinin were from Sigma Chemical Co. Immunohistochemical-grade 3,3Ј-diaminobenzidine was purchased from Biogenex.
Cell Culture
HUVECs were isolated and characterized as previously described. 24 The cells used for these studies were between the second and the fourth passage and had been derived from single cords and cultured in medium 199 supplemented with 2 mmol/L L-glutamine, 50 UI/mL penicillin, 50 g/mL streptomycin, 20% heat-inactivated FCS, 50 g/mL porcine intestinal heparin, and 50 g/mL crude extract of endothelial cell growth factor obtained from bovine hypothalamus. 25 
Determination of TF Activity by 1-Stage Clotting Assay
Confluent monolayers of HUVECs seeded in 12-well plates were washed 3 times with Hanks' balanced salt solution and incubated at 37°C for various times up to 24 hours in incubation medium (culture medium lacking FCS, heparin, and endothelial cell growth factor but containing the appropriate concentration of the test compounds or stock solvent; final concentration, maximally 0.1% vol/vol). Immediately before the assay, cells were lysed with 15 mmol/L octyl-␤-D-glycopyranoside at 37°C for 10 minutes and diluted with 25 mmol/L HEPES-saline. TF activity was determined as procoagulant activity by a one-stage plasma recalcification assay. 26 Clotting times were quantified by a standard curve obtained by serial dilution of a standard human thromboplastin (Thromborel, Behring) preparation. Preincubation of cells with a monoclonal antibody against TF (American Diagnostica Inc, Greenwich, Conn) blocked procoagulant activity by Ͼ90%, thus demonstrating the specificity of the assay. In addition, an assay performed with plasma from donors congenitally deficient in factor VII had no effect on clotting times. Data are expressed as units of TF activity per microgram of cell protein, as determined by the Bradford method. 27 
TF Staining
Immunostaining was performed using an antibody that specifically recognizes the extracellular domain (residues 1-218) of human TF (soluble TF antibody). 28 -30 For staining of living HUVECs, cells grown on 9.4-cm 2 chamber slides were either left untreated or were treated with rVEGF, rTNF-␣, or both as previously described. At the end of the incubation time, HUVECs were exposed to 1 g/mL soluble TF antibody for 30 minutes, washed, and fixed in PBS-4% p-formaldehyde, pH 7.4. Primary antibody was detected using a biotin-streptavidin-amplified detection system (SuperSensitive kit, Biogenex) and developed with 3,3Ј-diaminobenzidine. Slides were counterstained with hematoxylin, coverslipped, and examined by light microscopy. In most other studies, agonist-treated HUVECs were first fixed in PBS-4% p-formaldehyde, pH 7.4, and then incubated with 1 g/mL soluble TF antibody for 2 hours at 37°C. Primary antibody to soluble TF was detected as previously described. For confocal microscopy, the primary antibody was detected with fluoresceinated anti-rabbit IgG antibody (Sigma). Slides were examined using a Leica confocal laser scanning microscope. Positive control slides, nonimmune negative controls, and processing controls were performed for each antigen stain.
Determination of TF Activity by Monitoring Factor Xa Generation
TF activity was also assessed by monitoring hydrolysis of factor X. Confluent monolayers of HUVECs seeded on gelatin-coated, 9.4-cm 2 plastic chamber slides (Nunc) were incubated for various times in incubation medium containing the indicated agents. Duplicate sets of chamber slides were stimulated in each single experiment to allow for simultaneous determination of total (cell lysates) and surfaceassociated TF. To measure factor Xa generation in cell lysates, monolayers were lysed by incubation with 15 mmol/L octyl-␤-Dglycopyranoside for 15 minutes at 37°C. Factor VIIa (1 nmol/L) and factor X (150 nmol/L) were added sequentially. Aliquots of 40 L were taken every minute and added to 96-well plates, and the wells were filled with 100 L EDTA buffer (bicine buffer, pH 8.5: 25 mmol/L EDTA, 1 g/L BSA) to stop factor Xa production. Twenty-five microliters of a 15 mmol/L solution of IPR-pNA was added to each well, and absorption at the 405-nm wavelength was measured in a kinetic plate reader (Tmax, Molecular Devices). The concentration of factor Xa was calculated from the slope of the absorption curve. To measure factor Xa generation on the cell surface, the slides were mounted in a parallel-plate flow chamber (1 mL/min volumetric flow rate, which corresponds to a shear rate of 97 s Ϫ1 ). 31 Factors X and VIIa were continuously circulated for 15 minutes through the chamber by using a peristaltic pump. Every 3 minutes, a 40-L sample was taken and assayed for factor Xa as described above. All experiments were performed at room temperature. Femtomoles of TF per square centimeter were obtained by assuming a K cat of the TF/factor VIIa complex of 300 min Ϫ1 . This value is based on factor X titration to lysed HUVECs and a fixed amount (1 pmol/L) of factor VIIa. 
Determination of TF Antigen Levels
Western Blot Analysis
Cell lysates separated by SDS-polyacrylamide gel electrophoresis without reduction were transferred electrophoretically to nitrocellulose membranes (Schleicher & Schuell). The membranes were incubated overnight at 4°C in blocking buffer (20 mmol/L Tris hydroxide, pH 7.4; 137 mmol/L NaCl; 0.1% Triton X-100; and 5% dry skim milk) and then with an anti-TF monoclonal antibody at room temperature for 1 hour in blocking buffer. Membranes were washed in the same buffer without milk and incubated at room temperature for 1 hour with horseradish peroxidase-conjugated IgG sheep anti-mouse IgG. Immunoblots were developed using enhanced chemiluminescence (Amersham Corp).
[ 3 H]Leucine Incorporation
Protein synthesis in HUVECs was quantified by determination of the incorporation of [ 3 H]leucine into trichloroacetic acid (TCA) -precipitable radioactivity. In brief, cells grown to confluence in 12-well plates were incubated with 5 Ci/well of [ 3 H]leucine in the experimental medium in the presence or absence of the agents to be studied. FCS (20%) was used as the positive control. After 6 hours the cells were washed 3 times with cold PBS, and the proteins were precipitated by addition of 10% ice-cold TCA to each well for 30 minutes at 4°C. Wells were then washed twice with 95% ethanol. All TCA-precipitated material was solubilized in 0.1 mol/L NaOH and transferred to vials containing scintillation fluid, and radioactivity was counted in a beta counter.
RNA Purification and Northern Blot Analysis
Total cellular RNA was obtained according to Chomczynski and Sacchi. 32 RNA blot analysis was performed as described. 33 Ten micrograms of total RNA was loaded on each lane, and Northern blotting was performed by capillary transfer of RNA from the agarose gel to nitrocellulose membranes (Schleicher & Schuell BA-S NC; pore size, 0.45 m) with 20ϫ SSPE (0.75 mol/L NaCl, 0.05 mol/L NaH 2 PO 4 ⅐ H 2 O). Filters were prehybridized at 42°C for at least 2 hours in 50% deionized formamide, 5ϫ Denhardt's solution (0.1% Ficoll type 400, 0.1% polyvinylpyrrolidone, and 0.1% BSA), 5ϫ SSPE, 0.1% SDS, and 100 g/mL denatured salmon sperm DNA and hybridized at the same temperature and in the same solution with heat-denatured 32 P-labeled DNA probe for 16 to 24 hours. Blots were then washed once at room temperature and twice at 55°C for 20 minutes in 0.1% SDS, 2ϫ SSPE, followed by 2 washes at 55°C in 0.1% SDS, 0.1ϫ SSPE. Filters were exposed to Kodak XAR film at Ϫ80°C with intensifying screens. The level of GAPDH was used to normalize densitometric values for variations in RNA loads. Each experiment was performed in triplicate.
DNA Probes
The human TF cDNA probe was a 500-bp EcoRI fragment cloned into pUC19 obtained from the American Type Culture Collection, Manassas, Va. The human GAPDH probe was a 1469-bp BamHI fragment cloned into pBR322 kindly provided by Dr P. Castelli (Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy). The probes were labeled with [␣-32 P]dCTP (DuPont-NEN) by the random priming technique 34 to a specific activity of 5ϫ10 8 to 5ϫ10 9 counts per minute per microgram of DNA.
Statistical Analysis
The results are reported as meanϮSEM. ANOVA (1-way) followed by Tukey's test was used for determination of significance levels. A value of PϽ0.05 was considered significant.
Results
Effect of rVEGF and rTNF-␣ on TF Activity in HUVECs
Total TF activity was determined in cell lysates by using a one-stage clotting assay. Confluent HUVECs did not express detectable amounts of TF under basal conditions. In accord with previous reports, 7,8 500 U/mL rTNF-␣ markedly stimulated TF expression at 6 hours (Table 1) . rVEGF (0.001 to 1 nmol/L) also caused a concentration-dependent increase in TF activity (data not shown) with a Ͼ10-fold stimulation, compared with control, observed at 1.0 nmol/L ( Table 1) . The potential interaction between rVEGF and rTNF-␣ was studied at concentrations of each agent that by themselves induced substantial amounts of TF activity (1 nmol/L for rVEGF and 500 U/mL for rTNF-␣). Concomitant treatment of HUVECs with rVEGF and rTNF-␣ for 6 hours induced 10-fold more TF activity than did rTNF-␣ alone (Table 1) . Only concentrations of rVEGF (0.1 to 1.0 nmol/L) that were able to induce TF activity by themselves were synergistic with rTNF-␣ (Figure 1) . Total TF activity in HUVECs treated with rVEGF and rTNF-␣ used alone or in combination peaked at 6 hours ( Figure 2) . By 12 hours, the activity was reduced by half in all conditions, though remaining Ͼ6-or 20-fold higher in rVEGFϩrTNF-␣-treated cells than in cells treated with rTNF-␣ or rVEGF alone, respectively ( Figure 2) .
The synergistic effect of rVEGFϩrTNF-␣ on TF activity was paralleled by a marked increase in immunologically detectable TF protein, both by ELISA ( Figure 3A) and by Western blot analysis ( Figure 3B ). This was not due to a generalized synergistic increase in protein synthesis. Treatment of HUVECs with rVEGFϩrTNF-␣ did not significantly enhance total protein synthesis as measured by incorporation of [ 3 H]leucine (25Ϯ3.8%, 10Ϯ3.6%, and 19Ϯ3.6% increase over control in rVEGFϩrTNF-␣-, rVEGF-, and rTNF-␣-treated HUVECs, respectively, nϭ3; PϭNS). mRNA levels determined at 2 hours after stimulation with rVEGFϩrTNF-␣ were also markedly higher compared with single agenttreated cells (TF/GAPDH ratio in densitometric arbitrary units: control, 0.04; rVEGF, 0.5; rTNF-␣, 1.2; and rVEGFϩrTNF-␣, 1.6; Figure 3C ).
To assess whether the potentiating effect of rVEGF was specific for this growth factor, experiments with basic fibroblast growth factor (bFGF) and acidic FGF (aFGF)/heparin, alone or in combination with rTNF-␣, were performed. bFGF and aFGF/heparin alone did not affect TF activity in HUVECs (0.01Ϯ0.003 and 0.02Ϯ0.001 TF U/g cell pro- 
Induction of TF Activity by rVEGF and rTNF-␣ in HUVECs
Immunolocalization of TF in HUVECs
To identify TF accessible on the cell surface of HUVECs, monolayers of living cells were stimulated for 6 hours with rVEGF, rTNF-␣, or both and then incubated for 30 minutes with soluble TF antibody before fixation. Minimal staining was observed in untreated ( Figure 4A ) and in single agenttreated ( Figure 4B and 4C) cells, whereas the majority of the cells treated with both agonists showed intense membrane staining with some patchy cell surface distribution of TF ( Figure 4D ). Patches were further characterized on cells that were fixed 6 hours after treatment with rVEGFϩrTNF-␣ and then stained with the soluble TF antibody. By light ( Figure 4F and 4G) and confocal ( Figure 4H ) microscopy, the patches were detected as "buds" on the cell surface.
Effect of rVEGF and rTNF-␣ on Cell Surface-Associated TF
To determine the amount of TF expressed on the cell surface in response to agonists, HUVECs were grown on slides; incubated for 6 hours with rVEGF (1 nmol/L), rTNF-␣ (500 U/mL), or both; and then perfused with purified clotting factors in a parallel-plate flow chamber. To assess total TF activity, monolayers of HUVECs treated in the same manner were lysed, and factor Xa generation was measured. This confirmed the results obtained with the one-stage clotting assay ( Figure 5A ). Unstimulated cells had virtually no surface TF activity; rVEGF-or rTNF-␣-treated HUVECs also generated minimal amounts of surface TF activity (0.032 or 0.014 fmol of surface TF per cm 2 , respectively; Figure 5B ). On the contrary, the combination of agonists induced surface expression of Ϸ0.429 fmol of TF per cm 2 of confluent cell monolayer ( Figure 5B ). The peak of surface TF activity was observed 6 hours after stimulation ( Figure 6B ), similar to that of lysed samples ( Figure 6A ). Whereas lysed samples displayed a time-dependent accumulation of TF beginning at 2 hours ( Figure 6A ), increased expression on the cell surface was not seen until 6 hours ( Figure 6B ).
Discussion
The data presented in this study demonstrate that concomitant stimulation of HUVECs with rVEGF and rTNF-␣ induces endothelial cells to become highly thrombogenic due to a synergistic induction of surface TF activity. On the contrary, treatment of HUVECs with either agonist alone has minimal effect on surface TF activity expression.
TF is a transmembrane glycoprotein that serves as the initiator of coagulation. On its synthesis, TF is translocated to the cell surface, where it binds factor VIIa, thus triggering the coagulation cascade. Although TF protein has been found on the plasma membrane of a variety of cells 35 and on shed membrane vesicles in conditioned medium of cultured human monocytes 15, 36 and tumor cells, 37 studies attempting to localize sites of TF expression on endothelial cells have yielded controversial results. TF is located mainly on the basolateral side of the endothelial cell membrane 38 as well as on the apical surface. 19, 39 A predominant matrix-associated TF expression has also been reported. 30, 40 A finding common to these studies, however, is that stimulation of HUVECs with rTNF-␣, a strong inducer of TF mRNA and activity, results in minimal TF expression on the cell surface.
In this study, we have shown that rTNF-␣ and rVEGF increased TF mRNA, protein, and total activity as determined by the one-stage clotting assay or by factor Xa generation. In addition, the 2 agents had synergistic effects on the same parameters, in accordance with previous reports. 14 By using a parallel-plate flow chamber, which measures factor Xa generation on the cell surface of endothelial monolayers under dynamic conditions, we were able to detect only minimal surface TF activity on HUVECs exposed to concentrations of Figure 3 . TF antigen, protein, and mRNA determination in HUVECs treated with rVEGF, rTNF-␣, and rVEGFϩrTNF-␣. A, Cells were left untreated or were incubated with rVEGF (1 nmol/L), rTNF-␣ (500 U/mL), or rVEGFϩrTNF-␣ for 6 hours. At the end of the incubation, cell monolayers were solubilized and TF antigen was determined by ELISA as described. Data are the meanϮSEM of 3 experiments, each performed in duplicate. rVEGFϩrTNF-␣ versus control, rVEGF, and rTNF-␣: *PϽ0.01. B, For Western blot analysis, the cell lysates were fractionated by 10% SDS-polyacrylamide gel electrophoresis and processed as described in Methods. A representative of 5 experiments is shown. C, Confluent monolayers of HUVECs were left untreated or were incubated with rVEGF (1 nmol/L), rTNF-␣ (500 U/mL), or rVEGFϩrTNF-␣ for 1 hour. Northern blot analyses were performed with 10 g of total RNA per lane. The filters were also hybridized with a GAPDH probe as a control for loading. A representative of 3 experiments is shown.
rTNF-␣ that markedly increased total TF mRNA, protein, and activity. Similarly rVEGF, which also induces TF mRNA, protein, and activity, failed to significantly increase TF activity on the cell surface. Minimal expression of TF on the cell surface in response to either agonist was confirmed by immunolocalization of the protein on living cells. These data, together with the results of total TF activity measured in cell lysates, indicate that the majority of TF induced by rTNF-␣ or rVEGF appears not to be readily accessible on the cell surface.
This report also shows that stimulation of HUVECs by the combination of rTNF-␣ and rVEGF induced a marked increase in TF surface activity (30-and 15-fold compared with rTNF-␣ and rVEGF alone, respectively), which is out of proportion to the rise in total TF activity (4-and 8-fold, respectively). In this context it is interesting to note that doubling the concentration of rTNF-␣ resulted in a doubling of TF activity in the cell lysates but failed to increase the amount of surface TF synthesis (data not shown). These data suggest that only certain agonists or groups of agonists may be able to reveal surface TF activity.
The expression of active TF on the cell surface in response to rTNF-␣ϩrVEGF occurred with a time course distinct from that found for the induction of total TF activity measured in cell lysates. Of particular note, the increase in surface activity was transient and seen only between 5 and 6 hours after treatment. A similar kinetic pattern has been observed in smooth muscle cells. 29 The fate of surface TF is presently the object of several investigations. It has been recently proposed that in cells constitutively producing TF, the translocation of the protein into caveolae may represent a mechanism leading to downregulation of TF-initiated proteolytic function. 41, 42 This might explain the rapid decay in surface TF activity observed in this study.
The synergistic increase in endothelial cell TF activity induced by rVEGFϩrTNF-␣ was also observed by staining the surface of living cells with an anti-TF antibody. HUVECs showed a diffuse pattern of TF expression interspersed with patches of more densely staining material. By confocal microscopy, these patches appeared as buds on the cell surface. The buds might represent clumping of TF molecules, similar to that shown for a variety of receptors. 43 These Figure 4 . Immunolocalization of TF in living and fixed HUVECs. Confluent monolayers of HUVECs seeded on chamber slides were left untreated (A) or were incubated with rTNF-␣ (500 U/mL, B), rVEGF (1 nmol/L, C), or rTNF-␣ in combination with rVEGF (D) for 6 hours. At the end of the incubation time, cell monolayers were processed for soluble TF binding in living cells as described in Methods and examined by light microscopy (A, B, C, and D; magnification ϫ400). Monolayers of HUVECs seeded on chamber slides were left untreated (E) or were incubated with rTNF-␣ in combination with rVEGF (F, G, and H) for 6 hours. At the end of the incubation time, cell monolayers were fixed and processed for soluble TF binding as described in Methods and examined by light (E and F, magnification ϫ400; G, magnification ϫ1000) and confocal (H, magnification ϫ1000) microscopy.
clumps may ultimately be extruded from the cells into the culture medium or may be resorbed and degraded in lysosomes. 42 Indeed, the presence of small vesicles containing TF in the medium of stimulated endothelial cells has recently been described. 44 As previously mentioned, caveolaeassociated TF has also been proposed to contribute to endothelial regulation of hemostasis, owing to its colocalization with thrombomodulin and urokinase receptor. 42 The expression of TF is thought to be responsible for the thrombotic complications associated with septic shock, cancer, and atherosclerosis. [45] [46] [47] Our data suggest that endothelial cells process TF differently from monocytes, in that the surface expression of active TF appears to be more tightly regulated. This is not surprising, given the strategic position of endothelium as the lining of the luminal vessel surface, and it may have important implications in the regulation of thrombosis by endothelial cells. The ability of endothelial cells to generate active TF on their surfaces may require multiple agonists, and this mechanism may protect endothelial cells from acting as a procoagulant surface, even under stress conditions. VEGF has been used to induce angiogenesis in a rabbit ischemic hindlimb model 48 and to promote re-endothelialization in a model of carotid artery balloon injury, thereby attenuating neointimal thickening. 49 These studies have provided the impetus for the use of VEGF as a new therapeutic modality in the management of arterial insufficiency and intimal hyperplasia. 49 It should be noted that increased levels of TNF-␣ may also be present under these conditions. The synergistic effects of rVEGF and rTNF-␣ on endothelial cell surface TF expression may need to be taken into account in evaluating VEGF therapy. A, Confluent monolayers of HUVECs seeded on slides were left untreated or were incubated with rVEGF (1 nmol/L), rTNF-␣ (500 U/mL), or rTNF-␣ in combination with rVEGF for 6 hours. At the end of the incubation time, cells were lysed and assayed for total TF activity by evaluating factor Xa generation as described in Methods. Data are the meanϮSEM of 5 independent experiments. rVEGFϩrTNF-␣ versus control, rVEGF, and rTNF-␣: *PϽ0.01. B, Confluent monolayers of HUVECs seeded on slides were left untreated or were incubated with rTNF-␣ (500 U/mL), rVEGF (1 nmol/L), or rTNF-␣ϩrVEGF for 6 hours. At the end of the incubation time, the slides were mounted in a parallel-plate flow chamber, and TF activity was measured under flow conditions by evaluating factor Xa generation as described in Methods. Data are the meanϮSEM of 5 independent experiments. rVEGFϩrTNF-␣ versus control, rVEGF, and rTNF␣: *PϽ0.05. Figure 6 . Time course of total and surface TF activity in HUVECs treated with rTNF-␣ and rVEGF. A, Confluent monolayers of HUVECs seeded on slides were left untreated ( f ) or were incubated with rTNF-␣ (500 U/mL) in combination with rVEGF (1 nmol/L) (᭹) for different time periods up to 8 hours. At the end of each time point, cells were lysed and assayed for total TF activity by evaluating factor Xa generation as described in Methods. B, Confluent monolayers of HUVECs were left untreated ( f ) or were incubated with rTNF-␣ (500 U/mL) in combination with rVEGF (1 nmol/L) (᭹) for different time periods up to 8 hours. At the end of each time point, the slides were mounted in a parallel-plate flow chamber to measure cell surface-associated TF activity under flow conditions as described in Methods. A representative of 2 experiments performed in duplicate is shown.
